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Abstract
Axons require a constant supply of the labile axon survival factor Nmnat2 from their cell bodies to avoid spontaneous axon
degeneration. Here we investigate the mechanism of fast axonal transport of Nmnat2 and its site of action for axon
maintenance. Using dual-colour live-cell imaging of axonal transport in SCG primary culture neurons, we find that Nmnat2 is
bidirectionally trafficked in axons together with markers of the trans-Golgi network and synaptic vesicles. In contrast, there
is little co-migration with mitochondria, lysosomes, and active zone precursor vesicles. Residues encoded by the small,
centrally located exon 6 are necessary and sufficient for stable membrane association and vesicular axonal transport of
Nmnat2. Within this sequence, a double cysteine palmitoylation motif shared with GAP43 and surrounding basic residues
are all required for efficient palmitoylation and stable association with axonal transport vesicles. Interestingly, however,
disrupting this membrane association increases the ability of axonally localized Nmnat2 to preserve transected neurites in
primary culture, while re-targeting the strongly protective cytosolic mutants back to membranes abolishes this increase.
Larger deletions within the central domain including exon 6 further enhance Nmnat2 axon protective capacity to levels that
exceed that of the slow Wallerian degeneration protein, WldS. The mechanism underlying the increase in axon protection
appears to involve an increased half-life of the cytosolic forms, suggesting a role for palmitoylation and membrane
attachment in Nmnat2 turnover. We conclude that Nmnat2 activity supports axon survival through a site of action distinct
from Nmnat2 transport vesicles and that protein stability, a key determinant of axon protection, is enhanced by mutations
that disrupt palmitoylation and dissociate Nmnat2 from these vesicles.
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Introduction
The chimeric fusion protein WldS (Entrez Gene ID 22406)
affords robust protection of injured axons in vitro and in vivo [1,2]
and extends axon survival in several disease models [3–9]. The
WldS protein incorporates full-length Nmnat1 (Entrez Gene ID
66454), an NAD synthesising enzyme whose enzymatic activity is
necessary for the protective effect of WldS [10,11]. Additionally
WldS harbours an N-terminal region that causes its partial re-
distribution from the nucleus to an axoplasmic localization that is
necessary for axon protection in vivo [1,10–12]. We recently
identified the related NAD-synthetic enzyme Nmnat2 (Entrez
Gene ID 226518) as a labile, endogenous axon survival factor
whose constant supply from cell bodies into axons is required for
axon survival in primary culture. Specific depletion of Nmnat2
causes neurite degeneration without injury. After injury, endog-
enous Nmnat2 is depleted rapidly in the distal stump of neurites,
initiating the process of Wallerian degeneration. If the more long-
lived WldS protein is present in the axon, Nmnat2 is still depleted
at the same rate; however, the NAD-synthetic enzyme activity of
the stable WldS protein substitutes for that of Nmnat2, resulting in
a significant delay of Wallerian degeneration [13].
Supporting a role of Nmnat2 in axon survival, strong
overexpression of Nmnat2 delays Wallerian degeneration in vitro,
and this protective effect is dependent on its enzymatic activity
[13,14]. Furthermore, Nmnat2 overexpression delays injury-
induced axon degeneration in zebrafish [15] and alleviates
neurodegeneration in the P301L mouse model of tauopathy
[16]. Spontaneous synapse and axon loss in Drosophila lacking
dNmnat, which can be partially rescued by murine Nmnat2, also
supports a key role for endogenous axonal Nmnat activity in axon
survival [17].
Neurons are extremely polarized cells with processes extending
up to centimetres or even meters beyond the cell body. Moreover,
in some neurons the axon constitutes over 99% of total
cytoplasmic volume [18]. Despite growing evidence for the local,
axonal synthesis and regulation of some proteins [19–21], many
others appear to be synthesized only in the cell body and rely on
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axonal transport to reach their site of action in the axon or
synapse. This supply process is a huge logistical challenge, and not
surprisingly, any impairment affects axonal function or survival.
Indeed, recent work has illustrated that there is a significant, early
impairment in axonal transport in many neurodegenerative
conditions and, for at least some of these, impaired axonal
transport appears to cause the degenerative process [22].
Given that Nmnat2 is essential for axon maintenance [13] and
its mRNA has not been found in axons [23–26], the delivery of
this short-lived protein into axons is likely to limit axon survival
when axonal transport is impaired through injury, aging, or
disease. Although the WldS protein can overcome the need for
Nmnat2, its clinical application faces the problem that this gain-of-
function chimeric fusion protein is expressed only in WldS mice
and a few strains of transgenic organisms. Instead, understanding
and manipulating the delivery, turnover, or intra-axonal targeting
of the endogenous survival factor, Nmnat2, is a more promising
route to influence axon survival. Thus, it is important to
understand how healthy neurons ensure a steady supply of
Nmnat2 and the mechanisms that regulate its delivery, turnover,
and activity in axons.
Nmnat2 localizes to vesicular structures and undergoes fast
axonal transport in the neurites of primary culture neurons
[13,27]. Previous work showed that association of Nmnat2 with
Golgi membranes in HeLa cells requires palmitoylation of the two
adjacent cysteine residues C164/165. In the absence of these
residues, Nmnat2 adopts a more diffuse, cytosolic localization
[27,28]. This palmitoylation site is located within the isoform-
specific targeting and interaction domain (ISTID) of Nmnat2.
ISTID regions are found in all three mammalian Nmnat isoforms
and, in contrast to the more conserved core catalytic domains that
make up the remainder of the proteins, are highly divergent
between isoforms and are thus thought to account for the
differential subcellular localizations of the Nmnats [28].
Here we report that the small, centrally located exon 6 is both
necessary and sufficient for palmitoylation, stable membrane
association, and vesicle-mediated delivery of Nmnat2 into axons.
By manipulating its localization, we then test the hypotheses that
these transport vesicles are the sites of Nmnat2 axon-protective
action and that vesicular Nmnat2 is somehow protected from
rapid turnover, enabling it to reach the ends of long axons before
being degraded. Surprisingly, we find that a diffuse, nonvesicular
localization enhances Nmnat2 axon protection through increased
protein stability. Our results support a model in which Nmnat2
subcellular localization regulates its turnover and protective
capacity and suggest a site of action distinct from its transport
vesicles.
Results
Nmnat2 Is Delivered to Axons With a Golgi-Derived
Vesicle Population
Previously, we reported that, in primary culture neurons,
Nmnat2-EGFP is transported in particulate structures with an
anterograde bias and at velocities in the range of fast axonal
transport [13]. To shed light on the identity of this trafficking
organelle, we utilized dual-colour, live-cell imaging of primary
culture superior cervical ganglia (SCG) neurons to visualize the co-
transport of Nmnat2 with established axonal transport cargos and
organelle markers. Co-migration of two fluorescent markers was
quantified using kymographs (see Materials and Methods),
counting only moving particles. We detected significant co-
migration of Nmnat2 with several Golgi network markers (Golga2,
Syntaxin6, TGN38; Figure 1D–F, L). Similarly, high levels of co-
migration were observed for synaptic vesicle markers (SNAP25,
Synaptophysin, SynaptotagminI; Figure 1I–K, L). Interestingly,
however, no significant co-migration was found for mitochondria
(Figure 1A, L), lysosomes (lamp1; Figure 1B, L), or active zone
precursor vesicles (Bassoon; Figure 1G, L), and only partial co-
migration was detected for a marker of the ER-Golgi intermediate
compartment (ERGIC) (ERGIC53/LmanI; Figure 1C, L). Thus,
Nmnat2 undergoes fast axonal transport in a Golgi-derived vesicle
population that overlaps with synaptic vesicle precursors and is
distinct from mitochondria, lysosomes, active zone precursor
vesicles, and the ERGIC.
Nmnat2 Exon 6 Encodes Sequences Sufficient for Stable
Membrane Association and Axonal Transport
Next, we tested whether the reported mechanism of Golgi-
targeting in HeLa cells [27,28] applies to neuronal cell bodies and
vesicle targeting in axons. In order to define the requirements for
membrane association in neurons, we used a photoactivation assay
in SCG cell bodies. Photoactivatable GFP (PA_GFP [29]) was
fused to variant Nmnat2 sequences and microinjected along with
an mCherry marker to identify injected cells. PA_GFP was
activated in a small region of the cell body and the pool of
activated PA_GFP followed over time. For quantification, we
compared the fraction of fluorescence intensity that remained in
the activated area with a non activated area elsewhere in the cell
body (excluding the nucleus). Activated PA_GFP alone diffused
very rapidly throughout the cell body, resulting in an even
distribution of fluorescence after about 5–10 s (Figure 2). In
contrast, Nmnat2-PA_GFP was retained within the originally
activated area, suggesting strong membrane association that was
stable over the course of the experiment (Figure 2; Table 1). This
indicates that the majority of Nmnat2 is stably membrane-bound
and most of the spread of fluorescence that did occur was slow and
resulted from transport of vesicle-bound Nmnat2-PA_GFP out of
the activated region (see Figure 2A).
The C164/165 palmitoylation site is located at the centre of
the 27 amino acids encoded by exon 6 of Nmnat2 (see Figure
S1A for Nmnat2 primary structure with relevant regions
highlighted). To test whether this exon is sufficient for membrane
Author Summary
Neurons are polarized cells that rely on bidirectional
transport to deliver thousands of cargos between the cell
body and the most distal ends of their axons. One cargo
that is of particular importance is the NAD-synthesising
enzyme Nmnat2. This surprisingly unstable protein is
produced in the cell body and its constant supply into
axons is required to keep them alive. If this supply is
interrupted, Nmnat2 levels in the distal axon drop below a
critical threshold, leading to axon degeneration. The rapid
turnover of Nmnat2 contributes critically to the time
course of axon degeneration. If its half-life could be
extended, axons may be able to survive transient
interruptions of its supply. In this study, we find that
disruption of Nmnat2 localization to axonal transport
vesicles increases both its half-life and its capacity to
protect injured neurites. Specifically, association of
Nmnat2 with transport vesicles reduces it stability by
making it vulnerable to ubiquitination and proteasome-
mediated degradation. These findings suggest that mod-
ulation of the subcellular localization of Nmnat2 on
transport vesicles could serve as a potential avenue for
therapeutic treatment of axon degeneration.
Strong Axon Protection by Cytosolic Nmnat2
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targeting, we created an exon6-PA_GFP construct and subjected
it to the membrane association assay described above. Interest-
ingly, we observed a very strong membrane association that was
indistinguishable from that seen with full-length Nmnat2-
PA_GFP (Figure 2; Table 1). This same sequence also targeted
EGFP to transport vesicles in neurites that co-migrated with
full-length Nmnat2-mCherry. The degree of co-migration was
similar to that between Nmnat2-EGFP and Nmnat2-mCherry
(Figure 3B, C, and H). Together, these results indicate that exon
6 encodes residues sufficient for efficient, stable membrane
association and the resulting vesicular fast axonal transport of
Nmnat2.
Figure 1. Nmnat2 co-migrates with markers for trans-Golgi and synaptic vesicles. Co-migration was analysed using kymographs (time-
distance graphs) obtained from live-cell imaging of neurites from primary culture SCG neurons. Representative kymographs from neurites co-labelled
with Nmnat2-EGFP and (A) mito-tagRFP, (B) lamp1-RFP, or Nmnat2-mCherry and (C) LmanI-EGFP, (D) Golga2-EGFP, (E) Syntaxin6-EGFP, (F) TGN38-
EGFP, (G) GFP-Bassoon, (H) GAP43-EGFP, (I) SNAP25b-EGFP, (J) Synaptophysin-EGFP, and (K) SynaptotagminI-EGFP. (L) Quantification of co-migration.
The quantification shown for each construct represents the percentage of moving Nmnat2-labelled vesicles that were also labelled by the relevant
marker. Error bars indicate SEM.
doi:10.1371/journal.pbio.1001539.g001
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The C164/165 Palmitoylation Site and Surrounding Basic
Residues Are Required for Efficient Palmitoylation, Stable
Membrane Association, and Axonal Transport of Nmnat2
We then confirmed the requirement for the C164/165
palmitoylation site for membrane association in neurons, using a
C164S/C165S construct (Nmnat2DPS-PA_GFP; see Figure S1B
for an overview of all mutant constructs used in this study).
Photoactivation in SCG cell bodies resulted in a rapid spread of
fluorescence, similar to PA_GFP alone (Figure 2), although
quantification revealed that the spread was slightly slower than
for PA_GFP, even when accounting for differences in molecular
size (see k values in Table 1) [30], suggesting that other residues
contribute weakly to membrane association.
GAP43 (Entrez Gene ID 14432), which associates with
membranes through palmitoylation of a similar double-cysteine
motif, also requires an adjacent group of basic residues for efficient
and stable membrane association [31–33] and shows partial co-
migration with Nmnat2 (Figure 1H, L). We tested whether a
similar mechanism applies to Nmnat2 by mutating the five basic
residues encoded by exon 6 (K151A, K155A, R162A, R167A, and
R172A). This construct, Nmnat2DBR-PA_GFP, showed interme-
diate membrane association. A pool of diffusible material spread
quickly throughout the cell (as seen with PA_GFP), but a
significant portion of the signal remained in the originally
activated area for the duration of the experiment, suggesting the
presence of a pool of strongly membrane-bound material (as seen
with Nmnat2-PA_GFP and exon6-PA_GFP) (Figure 2). These
results suggest that, in addition to the palmitoylated cysteines
themselves, basic residues that surround C164/165 are also
required for efficient palmitoylation and membrane association.
However, the mobility of the diffusible portion of Nmnat2DBR-
PA_GFP was not significantly different from that of Nmnat2DPS-
PA_GFP (Figure 2; Table 1). Accordingly, a double mutant,
Nmnat2DPSDBR-PA_GFP, also showed the same mobility as
either of the single mutants, thus still exhibiting slower diffusion
than PA_GFP alone.
To confirm that these changes in membrane association reflect
the degree of palmitoylation of Nmnat2, we used radiolabelling to
measure palmitate incorporation into wild-type and mutant
Nmnat2 (Figure S2). In agreement with previous findings
[27,28] we found that FLAG-Nmnat2DPS loses all detectable
palmitoylation. Interestingly, however, a small but significant
portion of palmitate incorporation was maintained in FLAG-
Nmnat2DBR as predicted by the membrane association assay,
further supporting the idea that exon 6 basic residues are necessary
to enable efficient palmitoylation and only a small amount of
palmitoylation can occur in their absence. To further substantiate
the role of palmitoylation in Nmnat2 membrane association, we
treated SCG neurons with 2-Bromopalmitate (2-BP), a lipid-based
inhibitor of palmitoylation. As predicted, treatment with 2-BP
substantially reduced membrane association of wild-type Nmnat2-
PA_GFP in the photoactivation assay (Figure S6A, B).
Next, we sought to test the effect of exon 6 mutations on axonal
transport of Nmnat2. As expected, mutation of the palmitoylation
site in Nmnat2DPS-EGFP led to a diffuse, nonvesicular distribu-
tion in neurites. We detected little co-migration with Nmnat2-
mCherry (Figure 3E), which was not significantly different from
EGFP alone (Figure 3A, H). Like other cytosolic proteins,
nonspecific or transient membrane association may help deliver
this protein to neurites in this system [34]. For Nmnat2DBR-
EGFP, the amount of diffuse, nonvesicular fluorescence signal was
also greatly increased, but we still observed significant co-
migration with Nmnat2-mCherry (Figure 3D, H), consistent with
the residual palmitoylated, membrane-bound component inferred
from the photoactivation and palmitate labelling experiments.
Nmnat2DPSDBR-EGFP and Nmnat2Dex6-EGFP (lacking all of
exon 6) were both similar to Nmnat2DPS-EGFP with no further
reduction in co-migration with Nmnat2-mCherry (Figure 3F–H).
Taken together, these results suggest that, within exon 6, both the
palmitoylation site and surrounding basic residues are necessary
for efficient, stable membrane association, and vesicular axonal
transport of Nmnat2.
Loss of Nmnat2 Vesicle Targeting Increases Its Axon
Protective Capacity
We next tested the hypothesis that vesicle targeting is necessary
for Nmnat2-mediated axon protection. We injected wild-type or
variant Nmnat2-EGFP together with a DsRed2 fluorescent
marker into SCG cell bodies and transected their neurites 48 h
later. Due to its short half-life, Nmnat2-EGFP protects neurites for
24 h after transection only if strongly overexpressed. Surprisingly,
however, both Nmnat2DPS-EGFP and Nmnat2DBR-EGFP pre-
served transected neurites significantly more strongly when only
0.001 mg/ml of DNA was injected (Figure 4A, C). Interestingly, the
protective effects of these two mutations were additive. At
0.002 mg/ml, Nmnat2DPSDBR-EGFP showed strongly preserved
neurites up to 72 h, significantly more than either single mutant
(Figure 4B, D). To rule out any influence of the EGFP tag on these
results, we also found that untagged Nmnat2DPSDBR protects
neurites significantly better than untagged wild-type Nmnat2
(0.01 mg/ml; Figure S3). Thus, vesicle association is dispensable for
Nmnat2-mediated neurite protection in primary culture, and
missense mutations disrupting vesicle association boost Nmnat2
axon protective capacity to a modest but significant degree.
These surprising findings prompted us to investigate the effects
on axon protection of deletions within and around exon 6. In
particular, three deletion mutants were recently reported to retain
Figure 2. Exon 6 sequences are necessary and sufficient for Nmnat2 membrane association. (A) Use of photoactivatable GFP (PA_GFP)
fusion proteins to study Nmnat2 membrane association. Time course of a representative cell body of an SCG primary culture neuron injected with
each indicated construct is shown. The region of activation is marked by an orange circle in each image. (B) Quantification of protein mobility. Shown
is the percentage of fluorescence that remains in the originally activated area compared to a non activated area of equal size elsewhere in the cell
body. Error bars indicate SEM.
doi:10.1371/journal.pbio.1001539.g002
Table 1. Best-fit values for exponential decay of PA_GFP
diffusion in SCG cell bodies.
y‘ k
PA_GFP 0.51 0.56 (0.42+)
Nmnat2-PA_GFP 0.88 0.23
Exon6-PA_GFP 0.88 0.23
Nmnat2DPS-PA_GFP 0.53 0.18
Nmnat2DBR-PA_GFP 0.69 0.22
Nmnat2DPSDBR-PA_GFP 0.51 0.25
+k-value adjusted for difference in molecular size between PA_GFP and
Nmnat2-PA_GFP [30].
doi:10.1371/journal.pbio.1001539.t001
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enzyme activity (Nmnat2D32-EGFP, Nmnat2D43-EGFP,
Nmnat2D69-EGFP [35]). Remarkably, all these deletion mutants
and a mutant lacking exon 6 only (Nmnat2Dex6-EGFP) protected
neurites far more strongly than any of the missense constructs
above. Even microinjection of very low DNA concentrations
(0.0005 mg/ml) preserved around 80% of neurites for 72 h after
transection (Figure 5), compared with less than 10% for Nmnat2-
EGFP or Nmnat2DPSDBR-EGFP at this concentration. Surpris-
ingly, this even exceeds the level of protection achieved by WldS-
EGFP at this concentration (around 30% intact neurites at 72 h),
illustrating the very strong enhancement of axon protective
capacity in these mutants (Figure 5). The presence of the EGFP
tag was not necessary for the observed increase in protection
(Figure S4). To rule out the possibility that deletion of exon 6
induces a novel gain-of-function in Nmnat2 that is independent of
its NAD-synthesis activity, we introduced an enzyme-dead
mutation into Nmnat2Dex6. His24 is conserved in all three
mammalian Nmnats and is critical for Nmnat2 NAD-synthesis
activity as well as its ability to protect axons after cut [14,36,37].
Convincingly, a Nmnat2Dex6H24D enzyme-dead mutant did not
protect neurites after injury (Figure S5), although we found that
this mutation also reduces the stability of Nmnat2Dex6H24D
(unpublished data). Together, these findings suggest that, in
addition to the palmitoylation site and surrounding basic residues,
other exon 6 residues influence the axon protective capacity of
Nmnat2, while the additional sequences deleted outside of exon 6
in Nmnat2D32, Nmnat2D43, and Nmnat2D69 appear to have
little further effect.
Increased Neurite Protection Is Associated With Increased
Protein Stability and Reduced Ubiquitination
Next, we sought to identify the mechanism by which these
mutations increase axon protective capacity. As the short half-life
of Nmnat2 limits survival of injured axons [13], we decided to
investigate protein stability using an emetine chase assay. HEK293
cells transiently expressing FLAG-Nmnat2 or one of its mutant
forms were treated with 10 mM emetine to inhibit protein
synthesis. Nmnat2 turnover was then measured as the rate of
decline of the FLAG-Nmnat2 signal over time relative to a more
stable control (FLAG-WldS) [13]. We had envisaged that vesicular
Nmnat2 may be relatively stable, allowing it to reach the ends of
long axons, and in dynamic equilibrium with a less stable, but
perhaps more active cytosolic form. However, all mutations
Figure 3. Cytosolic Nmnat2 mutants do not co-migrate with wild-type Nmnat2 in neurites. Representative kymographs from neurites co-
labelled with Nmnat2-mCherry and (A) EGFP, (B) Nmnat2-EGFP, (C) exon6-EGFP, (D) Nmnat2DPS-EGFP, (E) Nmnat2DBR-EGFP, (F) Nmnat2DPSDBR-
EGFP, and (G) Nmnat2Dex6-EGFP. (H) Quantification of co-migration. The quantification shown for each construct represents the percentage of
moving wild-type Nmnat2-labelled vesicles that were also labelled by the relevant marker. Error bars indicate SEM. * and ** indicate statistically
significant difference compared to EGFP (* p,0.05, ** p,0.01, n.s. non-significant).
doi:10.1371/journal.pbio.1001539.g003
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Figure 4. Cytosolic Nmnat2 mutants show moderate increase in neurite protective capacity. (A) Representative fields of view of distal
primary culture SCG neurites 0 and 24 h after neurite cut, labelled by dsRed2 expression and injected with 0.001 mg/ml EGFP or the relevant Nmnat2-
EGFP variant. (B) Representative fields of view of primary culture SCG neurites 0 and 72 h after neurite cut, labelled by dsRed2 expression and injected
with 0.002 mg/ml EGFP or the relevant Nmnat2-EGFP variant. (C, D) Quantification of experiments in (A) and (B), respectively. Error bars indicate SEM. *
and ** indicate statistically significant difference compared to wild-type Nmnat2 (* p,0.05, ** p,0.01).
doi:10.1371/journal.pbio.1001539.g004
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disrupting membrane targeting were found to increase protein
stability (Figure 6A, B; Table 2). Moreover, the FLAG-
Nmnat2DPSDBR double mutant showed significantly higher
protein stability than either FLAG-Nmnat2DPS or FLAG-
Nmnat2DBR, supporting a model in which an increase in protein
stability contributes to the increase in protective capacity observed
for these missense mutations. Intriguingly, however, the very
strongly protective Nmnat2Dex6 construct was no more stable
than Nmnat2DPSDBR (Figure 6A, B; Table 2), suggesting that
factors other than protein stability underlie the further increase in
its protective capacity.
As Nmnat2 degradation is blocked by proteasome inhibitor
MG132 [13], we then asked whether Nmnat2 becomes ubiqui-
tinated and whether these stabilizing mutations reduce ubiquitina-
tion. Wild-type and mutant FLAG-Nmnat2 were overexpressed in
HEK293 cells, and the K48-specific ubiquitin binding domain of
Dsk2 was bound to Glutathione-Sepharose beads and used to
immunoprecipitate ubiquitinated proteins. An inactive mutant
form of the Dsk2 UBA was used as a control [38,39], and 20 mM
MG132 was added 6 h prior to cell lysis to increase the abundance
of ubiquitinated proteins. FLAG-Nmnat2 produced a clear ladder
of ubiquitinated products (Figure 6C), and all missense mutants
and Nmnat2Dex6 showed significantly less ubiquitination
(Figure 6C, D). Thus, reduced ubiquitination is likely to contribute
to the increased stability and protective capacity of these mutants.
Vesicle Localization Is Sufficient to Promote Nmnat2
Ubiquitination and Lower Axon Protective Capacity
Based on these results, we hypothesized that palmitoylation and
vesicle association cause wild-type Nmnat2 to become destabilised
through increased levels of ubiquitination. In contrast, the
nonvesicular, cytosolic location of the Nmnat2 mutants reduces
ubiquitination and increases protein stability and protective
capacity. The Nmnat2DPS data, and strongly enhanced protective
capacity of Nmnat2Dex6 over Nmnat2DPSDBR, indicate that the
observed effects do not just reflect removal of lysine residues. In
agreement with this model, inhibiting palmitoylation directly with
2-BP resulted in reduced levels of ubiquitination on FLAG-
Figure 5. Nmnat2 deletion mutants show substantial neurite protection up to 72 h. (A) Representative fields of view of distal primary
culture SCG neurites 0 and 72 h after neurite cut, labelled by dsRed2 expression and injected with 0.0005 mg/ml EGFP or the relevant Nmnat2-EGFP
variant or WldS-EGFP. (B) Quantification of experiment shown in (A). Error bars indicate SEM. * and *** indicate statistically significant difference
compared to wild-type Nmnat2 (* p,0.05, *** p,0.001).## indicates statistically significant difference compared to deletion mutants (## p,0.01).
doi:10.1371/journal.pbio.1001539.g005
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Nmnat2 (Figure S6C, D). Furthermore, 2-BP treatment enhanced
the half-life of FLAG-Nmnat2 in the emetine chase assay (Figure
S6E, F). Based on this, we predicted that a cytosolic, stable
Nmnat2 mutant with increased protective capacity (such as
Nmnat2DPSDBR) would revert to a wild-type behaviour when
re-targeted to vesicles. To test this, we first attached sequences to
the N-terminus of Nmnat2DPSDBR-PA_GFP that would re-target
it to the same Golgi-derived vesicle population as wild-type
Nmnat2. For this, we used exon 6 of Nmnat2 (Nmnat2DPSDBR-
Nterex6-PA_GFP) or the signal peptide and transmembrane
domain of TGN38 (Nmnat2DPSDBR-NterTGN-PA_GFP). These
constructs were stably targeted to membranes as assessed by the
photoactivation assay (Figure S7A, B), and as predicted, re-targeting
significantly reduced the ability to protect injured neurites
(Figure 7A, B). We also confirmed that Nmnat2DPSDBR-NterTGN
showed substantial levels of ubiquitination that were not detectable
Figure 6. Cytosolic Nmnat2 mutants exhibit increased protein stability and reduced levels of ubiquitination. (A) Representative
Western blots of HEK293 cells co-transfected with FLAG-WldS and the indicated FLAG-Nmnat2 variant. Twenty-four hours after transfection, cells were
treated with 10 mM emetine for the amount of time indicated after which samples were processed for SDS-PAGE and Western blot using anti-FLAG
antibody. (B) Quantification of Nmnat2 turnover after emetine treatment. For each sample and time point, the amount of FLAG-Nmnat2 remaining
was normalised to FLAG-WldS as an internal control. Error bars indicate SEM. (C) Representative Western blots of GST-Dsk2 pulldown assay. HEK293
cells expressing a FLAG-Nmnat2 variant were lysed (inp. – total input) and ubiquitinated proteins were immunoprecipitated using GST-Dsk2 bound to
glutathione beads (ubiq.). GST-fused mutant Dsk2 was used for control pulldown (cont.). Eluted proteins were processed for SDS-PAGE and analysed
by Western blot using anti-FLAG antibody. (D) Quantification of ubiquitination assay. For each Nmnat2 variant, the total amount of ubiquitinated
FLAG-Nmnat2 was normalised to total input. Error bars indicate SEM. ** and *** indicate statistically significant difference compared to wild-type
Nmnat2 (** p,0.01*** p,0.001).
doi:10.1371/journal.pbio.1001539.g006
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in Nmnat2DPSDBR (Figure 7E) and that the protein stability of
Nmnat2DPSDBR-NterTGN was significantly reduced as expect-
ed (Figure 7C, D).
While these results suggest that re-targeting cytosolic Nmnat2 to
membranes reverts its stability and protective capacity to lower
levels as expected, we cannot rule out the possibility that the N-
terminal sequences have a direct effect on Nmnat2 stability. To
address this issue, we used a commercially available heterodimer-
isation system (iDimerize, Clontech), in which two proteins tagged
with DmrC and DmrA domains, respectively, undergo hetero-
dimerisation after addition of a soluble ‘‘A/C heterodimeriser’’
compound [40]. We used TGN38-DmrC-HA to provide the
membrane anchor for re-targeting of cytosolic DmrA-
Nmnat2DPSDBR-PA_GFP based on the strong co-migration of
TGN38 with Nmnat2 (see Figure 1). Thus, this system overcomes
the abovementioned limitation of the N-terminal targeting
sequence as all that is required to induce membrane re-targeting
is addition of the small molecule heterodimeriser compound. The
photoactivation assay confirmed successful re-targeting, as mobil-
ity of DmrA-Nmnat2DPSDBR-PA_GFP was significantly reduced
after addition of heterodimeriser, albeit less strongly than using the
N-terminal targeting sequence above (Figure S8). Corresponding-
ly, addition of heterodimeriser also significantly reduced the axon
protective capacity of DmrA-Nmnat2DPSDBR-PA_GFP, but only
in the presence of TGN38-DmrC-HA (Figure 8A, B). Even though
the reduction in protective capacity observed in response to N-
terminal re-targeting was stronger than that achieved by
heterodimerisation, this was reflected in a lower degree of
membrane re-targeting in the heterodimerisation system (compare
Figure S7A, B and Figure S8). Additionally, we confirmed that re-
targeting of cytosolic Nmnat2DPSDBR to membranes through
heterodimerisation resulted in increased levels of ubiquitination
(Figure 8F, G) and a decreased protein half-life (Figure 8C–E),
confirming the results obtained with N-terminally re-targeted
mutants above.
At this point, it is interesting to ask whether the observed
changes after Nmnat2 re-targeting arise from a special property of
the vesicle membranes that Nmnat2 exon 6 and TGN38 target to,
or whether they reflect a more general effect of Nmnat2
membrane association. To test this, we attached the mitochondrial
outer membrane anchor (a.a. 1–37) of TOM20 to the N-terminus
of Nmnat2DPSDBR (Nmnat2DPSDBR-NterMOM). Note that, as
with Nmnat2DPSDBR-NterTGN, the Nmnat2 portion of this
construct faces the cytosol. The NterMOM tag led to stable
membrane association in the photoactivation assay (Figure S7A,
B). To confirm targeting to mitochondria, we co-stained neurons
expressing Nmnat2DPSDBR-NterMOM-PA_GFP with Mito-
Tracker dye and observed largely overlapping staining patterns
(Figure S7C). We then subjected Nmnat2DPSDBR-NterMOM to
the ubiquitination assay and found no evidence for increased levels
of ubiquitination relative to Nmnat2DPSDBR (Figure 7E). This
suggests that the induction of ubiquitination after membrane
attachment is indeed specific for transport vesicle membranes.
Despite the absence of detectable ubiquitination, however, we
found Nmnat2DPSDBR-NterMOM to be destabilized relative to
Nmnat2DPSDBR (Figure 7C, D), which resulted in a loss of
protective capacity (Figure 7A, B). These findings suggest that
targeting to the mitochondrial outer membrane destabilizes
Nmnat2 through a mechanism distinct from that operating on
transport vesicle membranes.
As described above, deletion of exon 6 led to a very strong
increase in Nmnat2 protective capacity without any further
changes in stability with respect to Nmnat2DPSDBR. To further
explore this dissociation between protective capacity and protein
stability, we re-targeted Nmnat2Dex6 to vesicle membranes using
the N-terminal TGN38 tag. Nmnat2Dex6-NterTGN was stably
targeted to membranes in the photoactivation assay (Figure S9)
and showed increased ubiquitination (Figure 9C) and reduced
protein stability (Figure 9D, E) with respect to Nmnat2Dex6.
Interestingly, however, this did not affect its protective capacity,
which remained indistinguishable from Nmnat2Dex6 up to 72 h
after cut (Figure 9A, B). This finding suggests that the increase in
protective capacity resulting from loss of exon 6 is sufficient to
strongly delay degeneration even when only a low, residual level of
protein remains.
Discussion
Nmnat2 is required for axon survival and is the only confirmed
endogenous Nmnat isoform in axons. However, its ability to
promote axon survival is limited by its short half-life. We have
identified a series of mutations that extend Nmnat2 half-life
without disrupting enzyme activity and which significantly
increase axon protection. For deletion mutants lacking exon 6
the efficacy even surpasses that of WldS. Surprisingly, these
changes arise when Nmnat2 targeting to a population of post-
Golgi axonal transport vesicles is disrupted and are reversed when
vesicle targeting is restored, indicating a nonvesicular site for the
axon survival function of Nmnat2. The more stable and protective
variants are less prone to ubiquitination through a mechanism
likely to involve subcellular targeting and not just lysine
availability. We identify cysteine-linked palmitoylation as the
vesicle targeting mechanism and propose modulation of this
targeting as a promising, novel therapeutic strategy for axono-
pathies.
We show that Nmnat2 axonal transport vesicles carry Golgi
markers as well as synaptic vesicle markers. In contrast, we find no
evidence of Nmnat2 undergoing co-transport with mitochondria.
This suggests that Nmnat2 is involved in the regulation of cytosolic
and not mitochondrial NAD metabolism in the axon, especially
since mitochondria are not thought to take up cytosolic NAD
under normal conditions [41]. Thus, any potential influence of
Nmnat2 on mitochondrial function is likely to be mediated
through indirect mechanisms. Furthermore, given that removal of
Nmnat2 from its vesicles does not impair its protective capacity, it
seems unlikely that Nmnat2 exists in close proximity to important
downstream targets on its own transport vesicles. If this were the
case, removal of Nmnat2 from this microenvironment would be
expected to result in reduced levels of neurite protection. Instead,
Table 2. Best-fit values for Nmnat2 wild-type and mutant
half-lives.
tK (h)
FLAG-Nmnat2 0.6
FLAG-Nmnat2 + 2-BP 1.1
FLAG-Nmnat2DPS 1.3
FLAG-Nmnat2DBR 1.8
FLAG-Nmnat2DPSDBR 3.6
FLAG-Nmnat2DPSDBR-NterTGN 1.0
FLAG-Nmnat2DPSDBR-NterMOM 0.9
FLAG-Nmnat2Dex6 3.4
FLAG-Nmnat2Dex6-NterTGN 0.9
doi:10.1371/journal.pbio.1001539.t002
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Figure 7. Re-targeting to membranes by N-terminal tags reduces neurite protection by Nmnat2DPSDBR through effects on
ubiquitination and protein stability. (A) Representative fields of view of distal primary culture SCG neurites 0 and 72 h after neurite cut, labelled
by dsRed2 fluorescence and injected with 0.001 mg/ml of Nmnat2DPSDBR-PA_GFP or one of its N-terminally membrane targeted variants
(Nmnat2DPSDBR-Nterex6-PA_GFP (Nterex6), Nmnat2DPSDBR-NterTGN-PA_GFP (NterTGN), and Nmnat2DPSDBR-NterMOM-PA_GFP (NterMOM). (B)
Quantification of experiment shown in (A). Error bars indicate SEM. ** and *** indicate statistically significant difference compared to Nmnat2DPSDBR
(** p,0.01, *** p,0.001). (C) Representative Western blots of HEK293 cells co-transfected with FLAG-WldS and FLAG-Nmnat2DPSDBR or one of its N-
terminally re-targeted variants (FLAG-Nmnat2DPSDBR-Nterex6 (Nterex6), FLAG-Nmnat2DPSDBR-NterTGN (NterTGN), and FLAG-Nmnat2DPSDBR-
NterMOM (NterMOM)). Twenty-four hours after transfection, cells were treated with 10 mM emetine for the amount of time indicated after which
samples were processed for SDS-PAGE and Western blot using anti-FLAG antibody. (D) Quantification of Nmnat2DPSDBR turnover after emetine
treatment. For each sample and time point the amount of FLAG-Nmnat2DPSDBR remaining was normalised to FLAG-WldS as an internal control. Error
bars indicate SEM. (E) Representative Western blot of GST-Dsk2 pulldown assay. HEK293 cells expressing a FLAG-Nmnat2DPSDBR variant were lysed
(inp. – total input), and ubiquitinated proteins were immunoprecipitated using GST-Dsk2 bound to glutathione beads (ubiq.). GST-fused mutant Dsk2
was used for control pulldown (cont.). Eluted proteins were processed for SDS-PAGE and analysed by Western blot using anti-FLAG antibody.
doi:10.1371/journal.pbio.1001539.g007
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it appears that the regulation of overall cytosolic NAD metabolism
by Nmnat2 is critical for axon survival.
Given the importance of axonal transport, surprisingly little is
known about sequences targeting proteins to axons. The
mechanism of Nmnat2 membrane association appears very similar
to that reported for another axonally transported protein, GAP43.
Both proteins lack a transmembrane domain or alternative mem-
brane targeting structures and depend fully on palmitoylation of a
double-cysteine motif for membrane association [27,28,42,43].
For GAP43, it was reported that, in addition to the palmitoylated
cysteine residues themselves, several adjacent basic amino acid
residues are also necessary for efficient membrane association [31–
33]. We found a similar mechanism to operate for Nmnat2. Our
results suggest that basic amino acid residues surrounding the
palmitoylation site in exon 6 are involved in mediating initial
membrane contact and allow palmitoylation to establish stable
membrane anchoring. In their absence, the level of palmitoylation
is strongly reduced and membrane targeting of Nmnat2 is less
efficient, resulting in a higher level of diffuse, soluble protein.
However, once palmitoylation has occurred, membrane associa-
tion seems to be as stable as for wild-type Nmnat2 over the time-
scale of our analysis. This view is also supported by our finding
that Nmnat2DBR, despite its increased level of diffuse fluorescence
in neurites, is still associated with the correct population of
transport vesicles. These similarities between GAP43 and Nmnat2
suggest a common underlying axonal targeting motif based on a
dual-cysteine palmitoylation site and adjacent or surrounding
lysine and arginine residues.
Palmitoylation regulates the axonal transport and subcellular
sorting of several axonally delivered proteins [44] and is unique
among the fatty-acid modifications in that it is readily reversible. It
is now well established that palmitate cycling, the recurrent
addition and removal of palmitate groups to a target protein, is an
important regulatory mechanism in many cases [45]. Thus it is
possible that endogenous Nmnat2 undergoes similar cycles of
palmitoylation and depalmitoylation. If this is the case, a model
could be envisaged in which Nmnat2 is palmitoylated and vesicle
bound for the purpose of delivery over long distances into axons.
Once in the axon, depalmitoylation could cause Nmnat2 to detach
from vesicles and instead assume a diffuse, cytosolic localization in
order to carry out its function in regulating axoplasmic NAD
metabolism. Thus, palmitate cycling would effectively regulate the
ratio of vesicle-bound to diffuse Nmnat2, and hence ultimately the
axon protective capacity of Nmnat2. Modulation of the Nmnat2
palmitoylation-depalmitoylation cycle by targeting the relevant
palmitoyltransferase and thioesterase enzyme(s) might hence
present a useful tool to alter the course of axon degeneration.
We also found support for the hypothesis that increased protein
stability underlies the mechanism by which diffuse, cytosolic
Nmnat2 becomes more highly protective. Wild-type Nmnat2,
which is mainly vesicle-bound, is very short-lived both in cell lines
and in the neurites of primary culture neurons [13]. Here we
found it to have a protein half-life of around 40 min, whereas
soluble, cytosolic Nmnat2 mutants have a longer half-life. This
means that while wild-type Nmnat2 is very rapidly depleted when
its supply stops after neurite transection, cytosolic mutants with
increased protein stability have an increased potency to protect
neurites against degeneration, due to a combination of higher
steady-state levels in the neurites before transection and a longer
protein half-life after transection. Moreover, the reduced level of
ubiquitination in these cytosolic mutants suggests that increased
protein stability is a direct result of reduced turnover of Nmnat2 by
the ubiquitin-proteasome system. This fits with our previous
findings that inhibition of the ubiquitin proteasome system, which
was shown to delay Wallerian degeneration [46], stabilizes
endogenous Nmnat2 [13]. Thus our data support a model in
which vesicle-bound Nmnat2 is unstable due to its high levels of
ubiquitination, which in turn results in its rapid turnover and short
protein half-life. Releasing Nmnat2 from its vesicles reduces
ubiquitination and leads to a more stable protein with a higher
axon protective capacity. Our results indicate that Nmnat2 can
undergo ubiquitination on lysine residues outside of exon 6 as
Nmnat2 mutants lacking exon 6 lysines (Nmnat2DPSDBR and
Nmnat2Dex6) can still be ubiquitinated when re-targeted to
membranes.
Interestingly, this destabilising effect of palmitoylation-mediated
membrane attachment contrasts with findings for several palmi-
toylated transmembrane domain proteins, including cell-surface
receptors [47–50] and SNARE proteins [51], for which it was
found that palmitoylation increases protein half-life through
reduction of ubiquitin-proteasome mediated degradation. Our
results indicate that the effect of palmitoylation on ubiquitination
and protein stability might differ for proteins lacking transmem-
brane regions (such as Nmnat2). The mechanism by which
palmitoylation-mediated vesicle-association causes high levels of
ubiquitination in Nmnat2 is as yet unclear and will be the object of
future studies. One interesting possibility is the localization of a
relevant ubiquitin ligase to the surface of Nmnat2 transport
vesicles. Such a vesicle-specific mechanism is supported by our
finding that re-targeting cytosolic Nmnat2 mutants to mitochon-
Figure 8. Membrane re-targeting through heterodimerisation causes ubiquitination, reduced protein stability, and impaired
neurite protection by Nmnat2DPSDBR. (A) Representative fields of view of distal primary culture SCG neurites 0 and 24 h after neurite cut,
labelled by dsRed2 fluorescence and injected with 0.002 mg/ml of DmrA-Nmnat2DPSDBR-PA_GFP plus 0.01 mg/ml TGN38-DmrC-HA or 0.001 mg/ml of
DmrA-Nmnat2DPSDBR-PA_GFP without any TGN38-DmrC-HA present. Eight hours before neurite cut, 500 nM of A/C heterodimeriser was added to
relevant cultures. (B) Quantification of experiment shown in (A). Error bars indicate SEM. ** indicates statistically significant difference compared to
control (** p,0.01). (C) Representative Western blots of HEK293 cells co-transfected with DmrA-Nmnat2DPSDBR-FLAG, FLAG-Nmnat1, and TGN38-
DmrC-HA (+TGN38-DmrC) or empty pCMV-Tag4A vector (-DmrC). To induce heterodimerisation, 500 mM A/C heterodimeriser were added to the
appropriate wells. Twenty-four hours after transfection, cells were treated with 10 mM emetine for the amount of time indicated, after which samples
were processed for SDS-PAGE and Western blot using anti-FLAG antibody. (D) Quantification of DmrA-Nmnat2DPSDBR-FLAG turnover after emetine
treatment when co-transfected with TGN38-DmrC-HA. For each sample and time point, the amount of DmrA-Nmnat2DPSDBR-FLAG remaining was
normalised to FLAG-Nmnat1 as an internal control. Error bars indicate SEM. (E) Quantification of DmrA-Nmnat2DPSDBR-FLAG turnover after emetine
treatment in the absence of TGN38-DmrC-HA. For each sample and time point, the amount of DmrA-Nmnat2DPSDBR-FLAG remaining was
normalised to FLAG-Nmnat1 as an internal control. Error bars indicate SEM. (F) Representative Western blot of GST-Dsk2 pulldown assay. HEK293 cells
expressing DmrA-Nmnat2DPSDBR-FLAG and TGN38-DmrC-HA and maintained in the absence (control) or presence (+heterodimeriser) of 500 mM A/C
heterodimeriser were lysed (inp – total input), and ubiquitinated proteins were immunoprecipitated using GST-Dsk2 bound to glutathione beads
(ubiq). GST-fused mutant Dsk2 was used for control pulldown (cont). Eluted proteins were processed for SDS-PAGE and analysed by Western blot
using anti-FLAG antibody. (G) Quantification of ubiquitination assay. For each condition, the total amount of ubiquitinated DmrA-Nmnat2DPSDBR-
FLAG was normalised to total input. Error bars indicate SEM. *** indicates statistically significant difference compared to control (*** p,0.001).
doi:10.1371/journal.pbio.1001539.g008
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drial outer membranes does not induce detectable ubiquitination.
Alternatively, vesicular axonal transport may deliver Nmnat2 to
parts of the axon with higher levels or activity of relevant elements
of the ubiquitin proteasome system. A recently published study
reported one such element regulating the turnover of Drosophila
Nmnat (dNmnat) in axons. The Drosophila E3 ubiquitin ligase
Highwire was found to be necessary and sufficient for rapid
turnover of dNmnat, and of ectopically expressed mammalian
Nmnat2, in the distal stump of injured axons. In its absence,
dNmnat persists and degeneration is delayed [52]. Together with
our findings, this suggests that ubiquitination regulates the course
of axon degeneration both in mammals and Drosophila and that
Nmnat2 axonal transport vesicles play an important role in
bringing together dNmnat or Nmnat2 with their respective
ubiquitin ligases.
Furthermore, our results indicate that subcellular localization
and protein stability are not the only determinants of Nmnat2
axon protective capacity. Deletion of exon 6 dramatically increases
Nmnat2-mediated neurite protection without any further increase
in protein stability. Our findings with the enzyme-dead exon 6
deletion mutant suggest that this strong increase in protective
capacity depends on Nmnat2 enzymatic activity. However, the
reduced stability of this mutant means we cannot completely rule
out the possibility that other, nonenzymatic mechanisms contrib-
ute to the rise in protective capacity. Interestingly, deletion of exon
6 overcomes the reduction in Nmnat2 protective capacity upon
membrane re-targeting that was observed for point mutants. This
rescue occurred despite the destabilising effects of membrane
attachment, which were unchanged by the removal of exon 6.
This suggests that exon 6 regulates Nmnat2 axon protective
Figure 9. Membrane re-targeting through N-terminal TGN38 tag causes ubiquitination and destabilization but does not impair
protective capacity of Nmnat2Dex6. (A) Representative fields of view of distal primary culture SCG neurites 0 and 72 h after neurite cut, labelled
by dsRed2 expression and injected with 0.0005 mg/ml Nmnat2Dex6-EGFP or Nmnat2Dex6-NterTGN-EGFP. (B) Quantification of experiment shown in
(A). Error bars indicate SEM. (C) Representative Western blot of GST-Dsk2 pulldown assay. HEK293 cells expressing FLAG-Nmnat2Dex6 or FLAG-
Nmnat2Dex6-NterTGN were lysed (inp. – total input), and ubiquitinated proteins were immunoprecipitated using GST-Dsk2 bound to glutathione
beads (ubiq.). GST-fused mutant Dsk2 was used for control pulldown (cont.). Eluted proteins were processed for SDS-PAGE and analysed by Western
blot using anti-FLAG antibody. (D) Representative Western blot of HEK293 cells co-transfected with FLAG-WldS and FLAG-Nmnat2Dex6 or FLAG-
Nmnat2Dex6-NterTGN. Twenty-four hours after transfection, cells were treated with 10 mM emetine for the amount of time indicated after which
samples were processed for SDS-PAGE and Western blot using anti-FLAG antibody. (E) Quantification of Nmnat2Dex6 turnover after emetine
treatment. For each sample and time point, the amount of FLAG-Nmnat2Dex6 remaining was normalised to FLAG-WldS as an internal control. Error
bars indicate SEM.
doi:10.1371/journal.pbio.1001539.g009
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function through various mechanisms, which could include
protein-protein interactions or additional posttranslational modi-
fications.
In summary, we show that Nmnat2, normally the least axon
protective of the three endogenous Nmnat isoforms due to its short
half-life, can be converted to a highly protective molecule by
disrupting its targeting to axonal transport vesicles. While the
importance of these vesicles for long-range axonal trafficking is
clear, we suggest that Nmnat2 must dissociate to carry out its axon
survival function optimally. We also propose that cytosolic NAD
metabolism is central to the axon survival mechanism. Our data
establish the principle that Nmnat2 can be modified to promote
axon survival and highlight modulation of its palmitoylation state
as a route to achieve this. Unlike WldS or other Nmnats, this
approach utilizes a protein already identified in wild-type axons,
raising the attractive prospect of converting an endogenous axonal
protein into one with a protective capacity that matches or even
exceeds that of WldS.
Materials and Methods
DNA Constructs
Nmnat2-EGFP, FLAG-Nmnat2, and FLAG-WldS constructs
were described previously [13]. WldS-EGFP was created by
insertion of the WldS coding sequence into the MCS of pEGFP-NI
vector (Clontech). Nmnat2-mCherry was created by replacing the
EGFP coding sequence of Nmnat2-EGFP with the mCherry
coding sequence from pmCherry-NI (Clontech). Nmnat2DPS-
EGFP, Nmnat2DBR-EGFP, and Nmnat2DPSDBR-EGFP were
created from Nmnat2-EGFP using the QuikChange II Site
Directed Mutagenesis Kit (Stratagene) according to the manufac-
turer’s instructions. Nmnat2Dex6-EGFP was created by PCR
amplification of the Nmnat2-EGFP vector excluding exon 6 and
introduction of a SacII restriction site to allow vector re-ligation.
FLAG-tagged, untagged, and PA_GFP tagged Nmnat2 wild-type
or mutants were created by insertion of the appropriate Nmnat2
mutant into the MCS of pCMV-Tag2A (Stratagene), pCMV-
Tag4A (Stratagene), and pPAGFP-NI [29] (Addgene plasmid
11909) vectors, respectively. Exon6-EGFP and Exon6-PA_GFP
constructs were created by PCR of exon6 from Nmnat2 and
insertion into the MCS of pEGFP-NI and pPAGFP-NI vectors.
DmrA-Nmnat2DPSDBR-PA_GFP was created by PCR amplifi-
cation of the DmrA coding sequence from pHet-NucI vector
(Clontech) and insertion at the N-terminus of Nmnat2DPSDBR-
PA_GFP. For the TGN38-DmrC-HA construct, the DmrC-HA
coding sequence was PCR amplified from the pHET-1 vector
(Clontech) and inserted in place of the GFP coding sequence of
TGN38-EGFP. Nmnat2DPSDBR-Nterex6-PA_GFP was created
by PCR amplification of Nmnat2 exon 6 and insertion at the N-
terminus of Nmnat2DPSDBR-PA_GFP. The N-terminal TGN38
targeting sequence was made by fusing the TGN38 signal peptide
sequence (a.a. 1–20) to its transmembrane domain surrounded by
linker sequences (a.a. 281–330). This sequence was then inserted
at the N-termini of Nmnat2DPSDBR and Nmnat2Dex6 to create
Nmnat2DPSDBR-NterTGN and Nmnat2Dex6-NterTGN, respec-
tively. Nmnat2DPSDBR-NterMOM was created by addition of
amino acids 1–37 of Mus musculus TOM20 to the N-terminus of
Nmnat2DPSDBR. Nmnat2Dex6H24D was created by site-direct-
ed mutagenesis of Nmnat2Dex6.
For organelle markers, the following accession numbers were
used for PCR primer design. Constructs were amplified frommouse
brain cDNA and inserted into the MCS of pEGFP-NI (Clontech) or
ptagRFP-NI (Evrogen) vectors. TGN38-EGFP, NM_009443;
Syntaxin6-EGFP, NM_021433; Synaptophysin-EGFP, NM_009305;
mito-tagRFP, AK003116 (bp 1–72); LmanI-EGFP, AK011495;
Golga2-EGFP, NM_133852; GAP43-EGFP, BC080758; Synap-
totagminI-EGFP, NM_001252341. All constructs were verified
by DNA sequencing (Beckman Coulter Genomics).
Nmnat2 deletion mutants (D32, D43, and D69) were a gift from
Prof. Giulio Magni (Ancona, Italy). GST-Dsk2 UBA was kindly
provided by Dr. Simon Cook (Cambridge, UK). The SNAP25-
EGFP construct was a gift from Dr. Luke Chamberlain (Glasgow,
UK). GFP-Bassoon was a gift from Prof. Eckart Gundelfinger
(Magdeburg, Germany). Lamp1-RFP [53] was from Addgene
(plasmid 1817).
Animals
All animal work was carried out in accordance with the Animals
(Scientific Procedures) Act, 1986, under Project License 80/2254.
C57BL/6JOlaHsd mice were obtained from Harlan UK (Bicester,
UK).
Primary Neuronal Cell Culture
Dissociated superior cervical ganglia cultures were prepared
and maintained in culture as described previously [13]. For live-
cell imaging of axonal transport, cells were transferred (on the
day of imaging) into imaging medium in order to improve
performance and detectability of fluorescent proteins [54]. Cells
were viable and appeared morphologically normal in imaging
medium for at least 3 days. Imaging medium consisted of
1.80 mM CaCl2 (Sigma), 0.25 mM Fe(NO3)3 (Sigma), 0.81 mM
MgSO4 (AnalaR), 5.33 mM KCl (AnalaR), 44.05 mM NaHCO3
(Sigma), 110.34 mM NaCl (AnalaR), 0.92 mM NaH2PO4
(Sigma), 4,500 mg/l glucose (AnalaR), 110 mg/l sodium pyr-
uvate(PAA), 2 mM glutamine (Invitrogen), 100 ng/ml 7S NGF
(Invitrogen), 1% penicillin/streptomycin (Invitrogen), 4 mM
aphidicolin (Calbiochem), 16 MEM amino acids (PAA),
30 mg/l glycine (AnalaR), and 42 mg/l serine (Sigma) in sterile
distilled water. For live-cell imaging of photoactivatable GFP
(PA_GFP), cells were transferred (on the day of imaging) into
Hibernate-E medium (Invitrogen) with added 2 mM glutamine
(Invitrogen), 100 ng/ml 7S NGF (Invitrogen), 1% penicillin/
streptomycin (Invitrogen), 2% B27 supplement (Invitrogen), and
4 mM aphidicolin (Calbiochem). For heterodimerisation, 500 nM
A/C heterodimeriser (Clontech) was added 8 h before imaging.
Where indicated, 40 mM 2-BP (Sigma) was added immediately
after microinjection.
Microinjection
DNA microinjections into the nuclei of primary culture SCG
neurons were performed as described [13]. For dual-labelling live
cell imaging, both DNA constructs were used at a concentration of
0.03 mg/ml in the injection mix. For single-color axonal transport
imaging, constructs were used at 0.05 mg/ml in the injection mix.
For photoactivation experiments, 0.05 mg/ml of the photoactiva-
tion construct was co-injected with 0.01 mg/ml mCherry expres-
sion construct except for experiments involving heterodimerisation
where 0.03 mg/ml each of DmrA- and DmrC-tagged constructs
were co-injected with 0.01 mg/ml mCherry expression construct.
Seventy-five cells were injected per dish, and imaging was
performed 24 h after microinjection. For experiments on neurite
degeneration after cut, 0.01 mg/ml DsRed2 expression vector was
co-injected with the relevant Nmnat2 constructs at varying
concentrations (see text). We injected 75–100 cells in each dish
and neurites were cut 48 h after microinjection. MitoTracker Red
CMXRos (Invitrogen) was used according to the manufacturer’s
instructions.
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Live Imaging of Axonal Transport and Image Analysis
Time-lapse imaging of axonal transport was performed on an
Olympus CellR imaging system (IX81 microscope, Hamamatsu
ORCA ER camera, 10061.45 NA apochromat objective, 485 and
561 nm laser excitation). During imaging, cell cultures were
maintained at 37uC in an environment chamber (Solent Scientif-
ic). Images were captured at 4 (single-color) or 2.5 (dual-colour)
frames per second for 1–2 min.
Co-Migration Analysis
The extent of axonal co-migration of two fluorescent protein
markers was analysed in time-lapse recordings of individual
neurites. Using ImageJ software version 1.44 (Rasband, W.S.,
ImageJ, NIH, Bethesda, Maryland, USA, http://imagej.nih.gov/
ij/, 1997–2011), the same neurite was straightened, contrast
adjusted, and projected as a kymograph for both image stacks.
The kymographs were then merged to create an overlay. Co-
migration was scored for each particle trace according to whether
it was detectable in only one or both of the kymograph channels.
Co-migration was determined only for moving particles (i.e., traces
that were not exclusively vertical in kymographs).
Quantification of Axonal Transport Parameters
Parameters of axonal transport of fluorescently labelled proteins
were determined from straightened time-lapse recordings of
individual neurites using the Difference Tracker ImageJ software
plugin [55]. Additionally, the percentage of moving and stationary
particles was scored manually on kymographs.
Photoactivation Imaging and Quantification
Photoactivation imaging was carried out on an Olympus FV1000
point scanning confocal microscope system (IX81 microscope,
6061.35 NA plan super apochromat objective, 488 and 561 nm
laser excitation). Microinjected cell bodies were identified based on
their mCherry fluorescence. Imaging settings were adjusted to
standard settings (56 zoom, scan rate 8 mm/s, frame rate 3 s/
frame). After taking a pre-activation image, PA_GFP was activated
by a 100 ms pulse of a 405 nm laser at 50% intensity in a 100 pixel
region of interest in the cell body. Images were then taken every 3 s
for a total of 5 min. For analysis, two circular regions of interest of
identical size (50 pixel diameter) were selected in the cell body. One
was placed in the originally activated area, while the other one was
placed 10–20 mm away in an area that was not activated by the
original laser pulse. For quantification, the percentage of combined
fluorescence in these two areas that remained in the originally
activated area was determined for each time point. Data were fitted
for exponential decay, and decay constant (k) was calculated using
GraphPad Prism 5.04.
Quantification of Neurite Degeneration
Degeneration of ds-Red2 labelled neurites was determined for
the same field of view at indicated time points after neurite
transection. The percentage of neurites remaining continuous and
morphologically normal compared to the initial time point was
scored for each field. For experiments involving heterodimerisa-
tion, A/C heterodimeriser (Clontech) was added to the relevant
dishes 8 h before cut at a final concentration of 500 nM. Fresh
medium (with heterodimeriser where appropriate) was added 24
and 48 h after cut.
HEK 293 Cell Culture and Transfection
HEK 293 cells were maintained in culture as described [13].
For transfection, cells were grown to 80% confluency in 10 cm or
24-well dishes and transfected using lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. For emetine
chase experiments, HEK293 cells in 24-well dishes were co-
transfected with WldS-FLAG and the appropriate FLAG-Nmnat2
construct (turnover of Nmnat2 mutants) or with Flag-Nmnat1,
TGN38-DmrC-HA, and DmrA-Nmnat2DPSDBR-FLAG (turn-
over of re-targeted mutants). For relevant experiments, 100 mM 2-
BP was added 6 h post-transfection. Twenty-four hours after
transfection, cells were treated with 10 mM emetine (Sigma) and
samples were taken at indicated time points.
For ubiquitination experiments, HEK293 cells in 10 cm dishes
were transfected with the appropriate FLAG-Nmnat2 construct
and, for re-targeting experiments, with empty pCMV-Tag4A or
TGN38-DmrC-HA constructs. Twenty-four hours after transfec-
tion, 20 mM MG132 (Sigma) was added to the medium. Six hours
later, cells were lysed and subjected to GST-Dsk2 UBA (wild-type
or mutant) pulldown assay as described [38,39]. Where indicated,
100 mM 2-BP was added 6 h post transfection.
Western Blotting
SDS-PAGE analysis and Western blotting analysis were
performed as described [13,56]. Mouse monoclonal anti-FLAG
(Sigma, M2) was used at 1:3,000. AlexaFluor680-conjugated anti-
mouse secondary antibody (Molecular Probes, Eugene, OR, USA)
was used at 1:5,000. Blots were scanned and quantified using the
Odyssey imaging system (LI-COR Biosciences, Lincoln, NC,
USA).
Palmitate Labelling
HEK293 cells in six-well dishes were transfected with the
appropriate FLAG-Nmnat2 construct. Twenty-four hours after
transfection, 0.5 mCi/ml [9,103H]-palmitate (Perkin Elmer) was
added to the medium. After 6 h, cells were washed in PBS, lysed in
500 ml lysis buffer (20 mM Tris pH 7.5, 137 mM NaCl, 1 mM
EGTA, 1% TritonX-100, 10% glycerol, 1.5 mM MgCl2, 50 mM
NaF, 1 mM Na3VO4, and protease inhibitor mix (Roche); all
chemicals AnalaR unless stated otherwise). The lysate was
centrifuged for 10 min, 13,000 rpm. Following overnight incuba-
tion of the lysate with 5 mg of anti-FLAG antibody (Sigma), 50 ml
of washed Sepharose beads (GE Healthcare) was added and mixed
for another 3 h at 4uC. Beads were washed thrice in lysis buffer
and twice in wash buffer (50 mM Tris, pH 8.0). Bound protein
was eluted with Laemmli sample buffer (BioRad) and boiling for
5 min and processed for SDS-PAGE. After transfer to PVDF
membrane, blots were dried and radiolabel was detected by
exposure on Tritium phosphor screen (Fuji) for 14 d.
Data Analysis
Statistical analyses and graph fitting were performed using
GraphPad Prism 5.04 (GraphPad Software Inc.) and SPSS
Statistics 19 (IBM).
Supporting Information
Figure S1 Nmnat2 primary structure and mutants. (A) Primary
structure of Mus musculus Nmnat2 with relevant regions highlight-
ed: ISTID region (underlined), exon 6 (blue), C164/165
palmitoylation site (red, bold), and exon 6 basic residues (K151,
K155, R162, R167, R172; orange). (B) Overview of Nmnat2
mutant constructs used in this study.
(TIF)
Figure S2 Palmitate labelling of Nmnat2 mutants. (A) Palmitate
label and Western blot of wild-type and mutant Nmnat2. HEK293
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cells expressing FLAG-Nmnat2 or one of its mutants were labelled
with 3H palmitate, subjected to FLAG-immunoprecipitation, and
processed for Phosphor Imaging and Western blot (see Materials
and Methods for details). (B) Quantification of palmitate
incorporation. Intensity of detected radiolabel was normalised to
FLAG signal on Western blot for each construct. For presentation,
mutant values were normalised to wild-type FLAG-Nmnat2. Error
bars indicate SEM. *** indicates statistically significant difference
between DPS and DBR mutants. (*** p,0.001).
(TIF)
Figure S3 Increased protection by untagged cytosolic Nmnat2
mutants. (A) Representative fields of view of primary culture SCG
neurites 0 and 24 h after neurite cut, labelled by dsRed2
expression and injected with 0.01 mg/ml empty vector or the
relevant untagged Nmnat2 variant. (B) Quantification of exper-
iment in (A). Error bars indicate SEM. * indicates statistically
significant difference compared to wild-type Nmnat2 (* p,0.05).
(TIF)
Figure S4 Untagged Nmnat2 deletion mutants are able to
strongly preserve neurites. (A) Representative fields of view of
distal primary culture SCG neurites 0 and 72 h after neurite cut,
labelled by dsRed2 expression and injected with 0.0005 mg/ml
empty vector or the relevant unlabelled Nmnat2 variant. (B)
Quantification of experiment shown in (A). Error bars indicate
SEM. *, **, and *** indicate statistically significant difference
compared to wild-type Nmnat2 (* p,0.05, ** p,0.01, ***
p,0.001).
(TIF)
Figure S5 Enzymatic activity is required for protection by
Nmnat2Dex6. (A) Representative fields of view of distal primary
culture SCG neurites 0 and 72 h after neurite cut, labelled by
dsRed2 expression and injected with 0.0005 mg/ml Nmnat2Dex6-
EGFP or enzyme-dead Nmnat2Dex6H24D. (B) Quantification of
experiment shown in (A). Error bars indicate SEM. ** indicates
statistically significant difference compared to Nmnat2Dex6 (**
p,0.01).
(TIF)
Figure S6 2-Bromopalmitate treatment impairs Nmnat2 mem-
brane targeting and extends Nmnat2 half-life. (A) Individual
frames from photoactivation assay of SCG primary culture
neurons expressing Nmnat2-PA_GFP in absence or presence of
40 mM 2-BP. (B) Quantification of protein mobility in (A). Error
bars indicate SEM. *** indicates statistically significant difference
compared to control (*** p,0.001). (C) Representative Western
blot of GST-Dsk2 pulldown assay. HEK293 cells expressing
FLAG-Nmnat2 in the presence or absence of 100 mM 2-BP. Cells
were lysed (inp – total input) and ubiquitinated proteins were
immunoprecipitated using GST-Dsk2 bound to glutathione beads
(ubiq). Eluted proteins were processed for SDS-PAGE and
analysed by Western blot using anti-FLAG antibody. (D)
Quantification of ubiquitination assay in (C). For each condition,
the total amount of ubiquitinated FLAG-Nmnat2 was normalised
to total input. Error bars indicate SEM. * indicates statistically
significant difference compared to control (* p,0.05). (E)
Representative Western blot of HEK293 cells co-transfected with
FLAG-WldS and FLAG-Nmnat2 in presence or absence of
100 mM 2-BP. Twenty-four hours after transfection, cells were
treated with 10 mM emetine for the amount of time indicated,
after which samples were processed for SDS-PAGE and Western
blot using anti-FLAG antibody. (F) Quantification of Nmnat2
turnover after emetine treatment in (E). For each sample and time
point the amount of FLAG-Nmnat2 remaining was normalised to
FLAG-WldS as an internal control. Error bars indicate SEM.
Half-life of Nmnat2 was significantly reduced by treatment with 2-
BP (from 45 to 65 min, p,0.01).
(TIF)
Figure S7 Successful re-targeting to membranes of
Nmnat2DPSDBR mutant by N-terminal tags. (A) Individual
frames from photoactivation assay of SCG primary culture
neurons expressing Nmnat2DPSDBR-PA_GFP or one of its N-
terminally membrane targeted variants (Nmnat2DPSDBR-
Nterex6-PA_GFP, Nmnat2DPSDBR-NterTGN-PA_GFP, and
Nmnat2DPSDBR-NterMOM-PA_GFP). The region of activation
is indicated by an orange circle in each image. (B) Quantification
of protein mobility in (A). Error bars indicate SEM. (C)
Representative images of cell bodies of primary culture SCG
neurons expressing Nmnat2DPSDBR-NterMOM-PA_GFP. The
whole cell body was subjected to a 405 nm laser pulse in order to
activate the entire pool of PA_GFP to enable co-localization
analysis. Cells were then stained with MitoTracker dye.
(TIF)
Figure S8 Successful membrane re-targeting of
Nmnat2DPSDBR mutant by heterodimerisation. (A) Photoactiva-
tion assay of SCG primary culture cell bodies co-expressing
DmrA-Nmnat2DPSDBR-PA_GFP and TGN38-DmrC-HA in the
absence (control) or presence of 500 mM A/C heterodimeriser for
8 h before imaging. The region of activation is indicated by an
orange circle in each image. (B) Quantification of protein mobility
in (A). Error bars indicate SEM.
(TIF)
Figure S9 Confirmation of re-targeting to membranes of
Nmnat2Dex6 by N-terminal TGN38 tag. (A) Individual frames
from photoactivation assay of SCG primary culture neurons
expressing Nmnat2Dex6-PA_GFP or Nmnat2Dex6-NterTGN-
PA_GFP. The region of activation is indicated by an orange
circle in each image. (B) Quantification of protein mobility in (A).
Error bars indicate SEM.
(TIF)
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